Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas

Journal of Neuro-Oncology

Volumn 102, Issue 2, 2011, Pages 317-321

  Ahluwalia, Manmeet S ^a   Patton, Carol ^a   Stevens, Glen ^a   Tekautz, Tanya ^a   Angelov, Lilyana ^a   Vogelbaum, Michael A ^a   Weil, Robert J ^a   Chao, Sam ^a   Elson, Paul ^a   Suh, John H ^a   Barnett, Gene H ^a   Peereboom, David M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Efficacy; Glioblastoma multiforme; HIV protease inhibitors; Matrix metalloproteases; Phase II; Ritonavir lopinavir

Indexed keywords

LOPINAVIR PLUS RITONAVIR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; BRAIN NEOPLASMS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GLIOMA; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRIMIDINONES; RITONAVIR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79953677463     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0325-3     Document Type: Article

References (22)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
2. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740
3. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578 (Pubitemid 29368260)
4. Lamborn KR, Yung WK, Chang SM et al (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-170
5. Burger PC, Dubois PJ, Schold SC Jr et al (1983) Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58:159-169 (Pubitemid 13190247)
6. Bussemakers MJ, Schalken JA (1996) The role of cell adhesion molecules and proteases in tumor invasion and metastasis. World J Urol 14:151-156 (Pubitemid 126775156)
7. Walker DG, Lavin MF (1997) The molecular genetics of astrocytomas: current understanding and future applications. J Clin Neurosci 4:114-121 (Pubitemid 127674800)
8. Anderson JC, McFarland BC, Gladson CL (2008) New molecular targets in angiogenic vessels of glioblastoma tumours. Expert Rev Mol Med 10:e23
9. Du R, Petritsch C, Lu K et al (2008) Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol 10:254-264
10. Liuzzi GM, Mastroianni CM, Latronico T et al (2004) Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain 127:398-407 (Pubitemid 38160324)
11. Sgadari C, Barillari G, Toschi E et al (2002) HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8:225-232 (Pubitemid 34250099)
12. Gaedicke S, Firat-Geier E, Constantiniu O et al (2002) Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 62:6901-6908 (Pubitemid 35424079)
13. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH (2002) The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62:5230-5235 (Pubitemid 35024595)
14. Pore N, Gupta AK, Cerniglia GJ, Maity A (2006) HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia 8:889-895
15. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ (2005) HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 65:8256-8265 (Pubitemid 41330590)
16. Pati S, Pelser CB, Dufraine J et al (2002) Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99:3771-3779 (Pubitemid 34534550)
17. Macdonald D, Cascino T, Schold SJ et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280 (Pubitemid 20195640)
18. http://www.rxabbott.com/pdf/kaletratabpi.pdf (Accessed 3/4/2010)
19. van Waterschott RA, ter Heine R, Wagenaar E et al (2010) Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 160(5):1224-1233
20. Cvetkovic RS, Goa KL (2003) Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 63(8):769-802 (Pubitemid 36432083)
21. Kumar GN, Jayanti VK, Johnson MK et al (2004) Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm Res 21(9):1622-1630 (Pubitemid 41184393)
22. Letendre SL, van den Brande G, Hermes A et al. and the HIV Neurobehavioral Research Center Group (2007) Lopinavir with tironavir reduces the HIV RNA level in cerebrospinal fluid. Clin Infect Dis 45(11):1511-1517 (Pubitemid 351411885)